BR112016013116A2 - Inibidores de trifluorometil pirazolil guanidina f1f0-atpase, seus usos, e composições farmacêuticas - Google Patents

Inibidores de trifluorometil pirazolil guanidina f1f0-atpase, seus usos, e composições farmacêuticas

Info

Publication number
BR112016013116A2
BR112016013116A2 BR112016013116A BR112016013116A BR112016013116A2 BR 112016013116 A2 BR112016013116 A2 BR 112016013116A2 BR 112016013116 A BR112016013116 A BR 112016013116A BR 112016013116 A BR112016013116 A BR 112016013116A BR 112016013116 A2 BR112016013116 A2 BR 112016013116A2
Authority
BR
Brazil
Prior art keywords
trifluoromethyl
guanidine
pirazolyl
pharmaceutical compositions
atpase inhibitors
Prior art date
Application number
BR112016013116A
Other languages
English (en)
Other versions
BR112016013116A8 (pt
Inventor
R Hurd Alexander
B Taylor Clarke
Wang Jian
Zhou Peng
Original Assignee
Lycera Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lycera Corp filed Critical Lycera Corp
Publication of BR112016013116A2 publication Critical patent/BR112016013116A2/pt
Publication of BR112016013116A8 publication Critical patent/BR112016013116A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

INIBIDORES DE TRIFLUOROMETIL PIRAZOLIL GUANIDINA F1F0-ATPASE E USO TERAPÊUTICO DOS MESMOS. A presente invenção fornece compostos de trifluorometil pirazolil guanidina que inibem F1F0-ATPase, e métodos de usar compostos de trifluorometil pirazolil guanidina como agentes terapêuticos para tratar distúrbios médicos, tal como um distúrbio imune, condição inflamatória, ou câncer.
BR112016013116A 2013-12-10 2014-12-10 inibidores de trifluorometil pirazolil guanidina f1f0-atpase, seus usos, e composições farmacêuticas BR112016013116A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361914085P 2013-12-10 2013-12-10
US201461979619P 2014-04-15 2014-04-15
PCT/US2014/069487 WO2015089149A1 (en) 2013-12-10 2014-12-10 Trifluoromethyl pyrazolyl guanidine f1fo-atpase inhibitors and therapeutic uses thereof

Publications (2)

Publication Number Publication Date
BR112016013116A2 true BR112016013116A2 (pt) 2017-08-08
BR112016013116A8 BR112016013116A8 (pt) 2020-05-12

Family

ID=53371791

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016013116A BR112016013116A8 (pt) 2013-12-10 2014-12-10 inibidores de trifluorometil pirazolil guanidina f1f0-atpase, seus usos, e composições farmacêuticas

Country Status (10)

Country Link
US (4) US9266839B2 (pt)
EP (1) EP3080089B1 (pt)
JP (1) JP6486364B2 (pt)
CN (1) CN105899489A (pt)
AU (1) AU2014363904B2 (pt)
BR (1) BR112016013116A8 (pt)
CA (1) CA2931851A1 (pt)
IL (1) IL245930A0 (pt)
MX (1) MX2016007445A (pt)
WO (1) WO2015089149A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9139532B2 (en) 2010-12-08 2015-09-22 Lycera Corporation Pyrazolyl guanidine F1F0-atpase inhibitors and therapeutic uses thereof
MX2013006398A (es) 2010-12-08 2013-12-02 Lycera Corp Inhibidores de f1f0-atpasas de tipo piridonilguanidina y usos terapeúticos.
EP2866796A4 (en) 2012-06-08 2015-11-25 Lycera Corp PYRAZOLYL GUANIDINE F1FO ATPASE HEMMER AND THERAPEUTIC USES THEREOF
WO2013185048A2 (en) 2012-06-08 2013-12-12 Lycera Corporation Heterocyclic guanidine f1f0-atpase inhibitors and therapeutic uses thereof
WO2013185046A1 (en) 2012-06-08 2013-12-12 Lycera Corporation Saturated acyl guanid1ne for inhibition of f1f0-atpase
JP2016539993A (ja) 2013-12-10 2016-12-22 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ Ｎ−置換ピラゾリルグアニジンｆ１ｆ０−ａｔｐアーゼ阻害剤及びその治療用途
EP3080089B1 (en) 2013-12-10 2019-05-08 Lycera Corporation Trifluoromethyl pyrazolyl guanidine f1fo-atpase inhibitors and therapeutic uses thereof
JP2016539983A (ja) 2013-12-10 2016-12-22 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ アルキルピラゾリルグアニジンｆ１ｆ０−ａｔｐアーゼ阻害剤及びその治療用途
CN116570589A (zh) * 2023-05-30 2023-08-11 南阳理工学院 化合物Parimifasor在制备抗肿瘤药物中的应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4977189A (en) * 1986-05-07 1990-12-11 American Cyanamid Company Substituted guanidinedicarbonyl derivatives
JPH07188197A (ja) 1993-11-17 1995-07-25 Fujisawa Pharmaceut Co Ltd オキサゾール誘導体
DE4344550A1 (de) 1993-12-24 1995-06-29 Hoechst Ag Substituierte 1-Oxo-1,2-dihydro-isochinolinoyl- und 1,1-Dioxo-2H-1,2-benzothiazinoylguanidine, Verfahrenzu ihrer Herstellung, ihre Verwendung als Medikamentt oder Diagnostikum sowie sie enthaltendes Medikamen
US7041702B1 (en) 1997-10-21 2006-05-09 Scion Pharmaceuticals, Inc. Pharmaceutically active compounds and methods of use
WO2000047207A1 (en) 1999-02-09 2000-08-17 Bristol-Myers Squibb Company LACTAM INHIBITORS OF FXa AND METHOD
US7276348B2 (en) 1999-04-30 2007-10-02 Regents Of The University Of Michigan Compositions and methods relating to F1F0-ATPase inhibitors and targets thereof
KR20020012310A (ko) 1999-07-15 2002-02-15 다께우찌 마사야쓰 복소 방향환 화합물
EP1296978A2 (en) 2000-06-30 2003-04-02 Bristol-Myers Squibb Company N-ureidoheterocycloaklyl-piperidines as modulators of chemokine receptor activity
WO2003050261A2 (en) 2001-12-10 2003-06-19 Bristol-Myers Squibb Company (1-phenyl-2-heteroaryl)ethyl-guanidine compounds as inhibitors of mitochondrial f1f0 atp hydrolase
GB0208224D0 (en) 2002-04-10 2002-05-22 Celltech R&D Ltd Chemical compounds
WO2003106628A2 (en) 2002-06-17 2003-12-24 Bristol-Myers Squibb Company Benzodiazepine inhibitors of mitochondial f1f0 atp hydrolase and methods of inhibiting f1f0 atp hydrolase
US7109224B2 (en) 2002-11-06 2006-09-19 Bristol-Myers Squibb Co. Acyl guanidine compounds and use thereof
WO2004050610A2 (en) 2002-12-04 2004-06-17 Gene Logic Inc. Modulators of melanocortin receptor
DE102004008141A1 (de) 2004-02-19 2005-09-01 Abbott Gmbh & Co. Kg Guanidinverbindungen und ihre Verwendung als Bindungspartner für 5-HT5-Rezeptoren
US20050272723A1 (en) 2004-04-27 2005-12-08 The Regents Of The University Of Michigan Methods and compositions for treating diseases and conditions associated with mitochondrial function
US20090275099A1 (en) 2004-04-27 2009-11-05 Regents Of The University Of Michigan Methods and compositions for treating diseases and conditions associated with mitochondrial function
AU2005262322B2 (en) 2004-07-01 2012-07-26 Synta Pharmaceuticals Corp. 2-substituted heteroaryl compounds
EP2037741B1 (en) 2006-06-09 2013-11-27 The Regents Of The University Of Michigan Benzodiazepine derivatives for use in the treatment of immune, inflammatory and proliferative disorders
CA2698248C (en) 2007-09-14 2017-08-29 The Regents Of The University Of Michigan Phenyl acyl guanidine derivatives as f1f0-atpase inhibitors and the use thereof
JP2011507910A (ja) 2007-12-21 2011-03-10 ユニバーシティー オブ ロチェスター 真核生物の寿命を変更するための方法
KR100982661B1 (ko) 2008-04-22 2010-09-17 전남대학교산학협력단 플라스멥신 ⅱ 활성을 저해하는 화합물을 유효성분으로함유하는 말라리아 예방 및 치료를 위한 약학 조성물 및이를 이용한 말라리아 치료방법
EP2352724B1 (en) 2008-09-11 2015-04-22 The Regents of the University of Michigan Aryl guanidine f1f0-atpase inhibitors and their medical use
MX2013006398A (es) 2010-12-08 2013-12-02 Lycera Corp Inhibidores de f1f0-atpasas de tipo piridonilguanidina y usos terapeúticos.
AU2011338302A1 (en) * 2010-12-08 2013-07-11 Lycera Corporation Cycloalkyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof
US9139532B2 (en) * 2010-12-08 2015-09-22 Lycera Corporation Pyrazolyl guanidine F1F0-atpase inhibitors and therapeutic uses thereof
US9169199B2 (en) 2010-12-08 2015-10-27 Lycera Corporation Cycloalkyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof
WO2013185048A2 (en) 2012-06-08 2013-12-12 Lycera Corporation Heterocyclic guanidine f1f0-atpase inhibitors and therapeutic uses thereof
WO2013185046A1 (en) 2012-06-08 2013-12-12 Lycera Corporation Saturated acyl guanid1ne for inhibition of f1f0-atpase
EP2866796A4 (en) 2012-06-08 2015-11-25 Lycera Corp PYRAZOLYL GUANIDINE F1FO ATPASE HEMMER AND THERAPEUTIC USES THEREOF
JP2016539983A (ja) * 2013-12-10 2016-12-22 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ アルキルピラゾリルグアニジンｆ１ｆ０−ａｔｐアーゼ阻害剤及びその治療用途
EP3080089B1 (en) 2013-12-10 2019-05-08 Lycera Corporation Trifluoromethyl pyrazolyl guanidine f1fo-atpase inhibitors and therapeutic uses thereof
JP2016539993A (ja) 2013-12-10 2016-12-22 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ Ｎ−置換ピラゾリルグアニジンｆ１ｆ０−ａｔｐアーゼ阻害剤及びその治療用途

Also Published As

Publication number Publication date
US9266839B2 (en) 2016-02-23
AU2014363904B2 (en) 2018-10-04
EP3080089A4 (en) 2017-08-23
US20190175556A1 (en) 2019-06-13
CA2931851A1 (en) 2015-06-18
AU2014363904A1 (en) 2016-06-30
JP2016539985A (ja) 2016-12-22
JP6486364B2 (ja) 2019-03-20
US20170354643A1 (en) 2017-12-14
CN105899489A (zh) 2016-08-24
EP3080089A1 (en) 2016-10-19
US20150183745A1 (en) 2015-07-02
US20160287559A1 (en) 2016-10-06
BR112016013116A8 (pt) 2020-05-12
MX2016007445A (es) 2016-09-09
EP3080089B1 (en) 2019-05-08
WO2015089149A1 (en) 2015-06-18
US9707211B2 (en) 2017-07-18
IL245930A0 (en) 2016-08-02
US10085972B2 (en) 2018-10-02

Similar Documents

Publication Publication Date Title
BR112016013116A2 (pt) Inibidores de trifluorometil pirazolil guanidina f1f0-atpase, seus usos, e composições farmacêuticas
CY1122098T1 (el) Παραγωγα ισοχρωμενιου ως αναστολεις κινασων φωσφοϊνοσιτιδης-3
SV2015005066A (es) Compuestos de biaril-amida como inhibidores de cinasa
BR112018000624A2 (pt) compostos de indazol e azaindazol como inibidores de irak-4
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
BR112018010464A2 (pt) formulações farmacêuticas tópicas para tratar condições inflamatórias relacionadas
PH12016501139B1 (en) Bicyclic heterocycle compounds and their uses in therapy
NI201600071A (es) Compuestos de inhibidor de autotaxina
UY36342A (es) Nuevos derivados de aminoalquilbenzotiazepinas y usos de los mismos
BR112016018555A8 (pt) Ciclopropilaminas como inibidores de lsd1, seu uso, composição farmacêutica que os compreende e método de inibição de lsd1
BR112017006940A2 (pt) triazolopirazinonas como inibidores de pde1
ECSP16008797A (es) Derivados de heterobicicloaril como inhibidores rorc2 y métodos de uso de los mismos
BR112016003201A2 (pt) inibidores de grp94 seletivos e usos dos mesmos
EA201692313A1 (ru) Производные индолизина в качестве ингибиторов фосфоинозитид-3-киназ
BR112019021867A2 (pt) Compostos de fenil-2-hidroxi-acetilamino-2-metil-fenil
BR112017009552A8 (pt) Métodos para alvejar o controle transcricional em regiões de super-realçador
PL410665A1 (pl) Inhibitory arginazy oraz ich zastosowania terapeutyczne
MX344590B (es) Inhibidores de f1f0-atpasas de tipo pirazolilguanidina y sus usos terapéuticos.
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
UY35747A (es) Derivados sustituidos de fenilalanina
WO2013185048A3 (en) Heterocyclic guanidine f1f0-atpase inhibitors
EA201691570A1 (ru) Фармацевтическая композиция, включающая диамино-гетероциклическое карбоксамидное соединение в качестве активного ингредиента
EA201791933A1 (ru) Ингибирование активности olig2
ECSP16061208A (es) Quinazolin-thf-aminas como inhibidores de pde1
BR112014024033A8 (pt) Formulação vesicular, método para o tratamento da rosácea e uso de um ou mais fosfo, sulfolipídios e surfactantes

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements